Anti-Mouse IGF-I - Biotin
| Code | Size | Price |
|---|
| LEI-I-240-50ug | 50 ug | £762.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Biotin
Format:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Formulation:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Immunogen:
Purified Recombinant Mouse IGF-I (Accession # Q8CAR0)
Long Description:
The IGFs are mitogenic polypeptide growth factors that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar by structure and function to insulin, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but, IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions.
NCBI Gene:
16000
Target:
IGF-I
Related Products
| Product Name | Product Code | Supplier | Anti-Human IGF-I | LEI-I-142 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human IGF-I | LEI-I-180 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IGF-I - Biotin | LEI-I-235 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Mouse IGF-I | LEI-I-239 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Rat IGF-I | LEI-I-524 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IGF-I (Clone 56408) | LEI-I-649 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IGF-I (Clone 126002) | LEI-I-709 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||